Aldose reductase drives hyperacetylation of EGR-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals

63Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Sustained increases in glucose flux via the aldose reductase (AR) pathway have been linked to diabetic vascular complications. Previous studies revealed that glucose flux via AR mediates endothelial dysfunction and leads to lesional hemorrhage in diabetic human AR (hAR) expressing mice in an apoE2/2 background. Our studies revealed sustained activation of Egr-1 with subsequent induction of its downstream target genes tissue factor (TF) and vascular cell adhesion molecule-1 (VCAM-1) in diabetic apoE2/2hAR mice aortas and in high glucose-treated primary murine aortic endothelial cells expressing hAR. Furthermore, we observed that flux via AR impaired NAD+ homeostasis and reduced activity of NAD+-dependent deacetylase Sirt-1 leading to acetylation and prolonged expression of Egr-1 in hyperglycemic conditions. In conclusion, our data demonstrate a novel mechanism by which glucose flux via AR triggers activation, acetylation, and prolonged expression of Egr-1 leading to proinflammatory and prothrombotic responses in diabetic atherosclerosis. © 2014 by the American Diabetes Association.

Cite

CITATION STYLE

APA

Vedantham, S., Thiagarajan, D., Ananthakrishnan, R., Wang, L., Rosario, R., Zou, Y. S., … Ramasamy, R. (2014). Aldose reductase drives hyperacetylation of EGR-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals. Diabetes, 63(2), 761–774. https://doi.org/10.2337/db13-0032

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free